High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule
This trial is active, not recruiting.
|Treatment||hdr interstitial brachytherapy|
|Sponsor||British Columbia Cancer Agency|
|Start date||May 2012|
|End date||December 2013|
|Trial size||15 participants|
|Trial identifier||NCT01605097, H12-00557|
This study will investigate the feasibility of using technology of ultrasound guided HDR brachytherapy to focally increase dose to regions within the prostate that are heavily infiltrated with cancer. Such regions, referred to as dominant intraprostatic lesions (DIL) can be visualized using diffusion contrast enhanced MRI employing an endo-rectal coil. The magnetic resonance (MR) images can be fused with the planning transrectal ultrasound (TRUS) prior to the brachytherapy procedure to design a dose distribution that will encompass the malignant volume with higher than the prescription dose. By its nature, brachytherapy has subvolumes that receive (for example)125% of the prescription dose or 150% of the prescription dose. With TRUS-guided and TRUS-planned HDR these areas can be manipulated to coincide with the DIL. The limit of dose escalation has been reached at whole prostate external beam doses of 81-86 Gy and still failure rates for intermediate and high risk disease are unacceptable. There is much interest in focal dose escalation and TRUS-guided HDR brachytherapy is perfectly suited to achieving this.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Feasibility of delivery of a higher than prescription dose to the dominant intra-prostatic nodule as defined on diffusion contrast-enhanced endo-rectal MRI, while respecting tolerance doses of adjacent normal organs.
time frame: 12 months
Acute toxicity compared to a cohort of 25 patients treated to standard dose
time frame: 24 months
Efficacy will be assessed by repeat DCE MRI at 12 months and TRUS-guided prostate biopsy at 30 months.
time frame: 30 months
Male participants from 40 years up to 80 years old.
Inclusion Criteria: - histologically proven adenocarcinoma of the prostate - intermediate or high risk prostate cancer - Intermediate risk prostate cancer patients must have: - Clinical stage ≤ T2c, - Gleason score = 7 and initial prostate specific antigen (iPSA) ≤ 20, or - Gleason score ≤ 6 and iPSA > 10 and ≤ 20. - High risk patients may have - Clinical stage T3 - Gleason score 8-10 - PSA > 20 ng/ml - fit for general anesthetic. - unilateral disease with either a palpable nodule or a cluster of positive biopsies from a single region suggesting the presence of dominant nodule. - estimated life expectancy of at least 10 years. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2. - no contraindications to interstitial prostate brachytherapy. - if on coumadin therapy must be able to stop safely for 7 days. - must not have any contraindications to MRI Exclusion Criteria: - Does not meet staging criteria for intermediate or high risk prostate cancer - Does not have a localized high volume of intraprostatic disease - unfit for general anesthetic - MRI contraindicated - unable to stop blood thinners - Life expectancy < 10 years
|Official title||High Dose Rate Prostate (HDR) Brachytherapy Dose Escalation to Dominant Intra-prostatic Nodule for Patients With Intermediate and High Risk Prostate Cancer|
|Principal investigator||Matthew Schmid, MSc|
|Description||Methods: If a dominant nodule is visualized on dynamic contrast enhanced (DCE) MRI, it will be contoured in 3D and the images fused to the planning TRUS study that is done in preparation for brachytherapy (of any type: seeds or HDR). The patient's treatment will consist of the standard combined external beam (4600 centiGray (cGy) in 23 fractions) and HDR brachytherapy boost (2 fractions of 1000 cGy given on days 5 and 15 of the external beam course). During each HDR treatment the plan will be manipulated such that the normally occurring high dose regions (125%, 150%) are positioned at the site of the identified disease. Normally approximately 60% of the prostate volume receives 125% of the dose and 30% receives 150%. By ensuring that the inherent dosimetry favors treatment of the known cancer, no region of the prostate would be "underdosed". HDR treatments are performed under general anesthesia as an out patient procedure. Statistical Analysis: This is a feasibility study and the data reported will be descriptive including the frequency with which the DIL can be visualized in this population, the DIL volume compared to total prostate volume, and the isodose that can encompass the DIL without violating dose constraints to adjacent organs (urethra and bladder). Toxicity will be monitored and efficacy will be assessed by repeat DCE MRI at 12 months and biopsy at 30 months.|
Call for more information